---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-119506"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:33:50.882083+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcellx reports 97% ORR and 68% CR/sCR in Phase 2 anito-cel study for RRMM

## Summary
- Phase 2 iMMagine-1 (117 patients) showed 97% ORR and 68% CR/sCR at median 12.6 months follow-up.
- No delayed neurotoxicities (Parkinsonism, cranial nerve palsies, Guillain-Barré) or immune-mediated enterocolitis.
- 12-month PFS rate 78.8%, OS rate 95.2%; median PFS and OS not reached.
- Data to be presented at EHA2025 on June 14; commercial launch with Kite planned for 2026.

## SEC filing metadata
- accession: 0001193125-25-119506
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000119312525119506/0001193125-25-119506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000119312525119506/d941498d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-119506
- JSON: https://secwatch.observer/filing/0001193125-25-119506.json
- Plain text: https://secwatch.observer/filing/0001193125-25-119506.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.